常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.08/-0.99
|
|
企業價值
39.06M
|
| 資產負債 |
|
每股賬面淨值
0.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
14.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/18 12:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others. |

1.49 
